A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Crenigacestat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly
- 02 Jun 2017 Results(n=22) assessing tumor response presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 10 Apr 2017 Protocol has been amended to change in the treatment arm from 2 to 4 and change in patient number.
- 04 Apr 2017 Planned number of patients changed from 227 to 282.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History